STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in patients with advanced BRCA-mutant breast cancer is relatively modest. Using a syngeneic genetically-engineered mouse model of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiwei, Bergholz, Johann S., Ding, Liya, Lin, Ziying, Kabraji, Sheheryar K., Hughes, Melissa E., He, Xiadi, Xie, Shaozhen, Jiang, Tao, Wang, Weihua, Zoeller, Jason J., Kim, Hye-Jung, Roberts, Thomas M., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Dillon, Deborah A., Winer, Eric P., Lin, Nancy U., Zhao, Jean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156717/
https://www.ncbi.nlm.nih.gov/pubmed/35641483
http://dx.doi.org/10.1038/s41467-022-30568-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156717/
https://www.ncbi.nlm.nih.gov/pubmed/35641483
http://dx.doi.org/10.1038/s41467-022-30568-1

Ejemplares similares